MedTrace Logo

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

NCT00418145 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-05-18

Study results available
· View outcomes & findings →

Summary

This clinical trial compares the relative efficacy of treating acute exacerbations of relapsing forms of Multiple Sclerosis with equivalent doses of oral and intravenous (IV) methylprednisolone. This is a randomized, blinded, multi-center study.

Conditions

Interventions

DRUG

megadose oral methylprednisolone

1400 mg qd/5 days

DRUG

IV methylprednisolone

1000 mg/qd/5 days

Sponsors & Collaborators

  • National Multiple Sclerosis Society

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Fred Lublin

    lead OTHER

Principal Investigators

  • Fred Lublin, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418145 on ClinicalTrials.gov